GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded ...
A first-in-human multicenter trial found the UltiSynq CSP ICD lead, designed for left bundle branch area pacing, met and exceeded safety and effectiveness goals in over 200 patients needing ICD or CRT ...
Please provide your email address to receive an email when new articles are posted on . A bipolar conduction system pacing implantable cardioverter defibrillator lead met safety and effectiveness ...
A dedicated bipolar implantable cardioverter-defibrillator (ICD) lead for conduction system pacing (CSP) performed well in a first-in-human multicenter study. Placement of the novel UltiSynq CSP ICD ...
Conduction-system pacing (CSP) was put to the test in two randomized trials of patients requiring cardiac resynchronization therapy (CRT) for left bundle branch block (LBBB)—the HeartSync-LBBP and ...
Discordant results from two trials comparing conduction system pacing with biventricular pacing for cardiac resynchronization therapy (CRT) leave open the question of whether conduction system pacing ...
Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results